The risk factors of severe acute kidney injury induced by cisplatin

Oncology (Switzerland)

Volumn 85, Issue 6, 2013, Pages 364-369

  Mizuno, Tomohiro ^a,b   Ishikawa, Kazuhiro ^b   Sato, Waichi ^b   Koike, Takahiro ^a   Kushida, Mayu ^a   Miyagawa, Yasuhiro ^b   Yamada, Kiyofumi ^b   Hirata, Sumio ^c   Imai, Enyu ^b   Noda, Yukihiro ^a  

^a MEIJO UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Acute kidney injury; Advanced cancer; Cardiovascular disease; Cisplatin; Diabetes mellitus

Indexed keywords

BLEOMYCIN; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GIMERACIL; IRINOTECAN; METHOTREXATE; NAVELBINE; NIMUSTINE; OTERACIL; POTASSIUM; SODIUM; TAMOXIFEN; TEGAFUR; VINBLASTINE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLADDER CANCER; BODY SURFACE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FEMALE; GINGIVA TUMOR; GLOMERULUS FILTRATION RATE; HUMAN; JAPANESE (PEOPLE); KIDNEY PELVIS CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVARY CANCER; PARANASAL SINUS CANCER; PHARYNX CANCER; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RECTUM CANCER; RETROSPECTIVE STUDY; RISK FACTOR; SODIUM BLOOD LEVEL; STOMACH CANCER; TESTIS CANCER; TREATMENT DURATION; UTERINE CERVIX CANCER;

ACUTE KIDNEY INJURY; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; COHORT STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84892176581     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000356587     Document Type: Article

References (15)

1. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704.
2. Mizuno T, Sato W, Ishikawa K, et al: KDIGO (Kidney Disease: Improving Global Outcomes) criteria could be a useful outcome predictor of cisplatin-induced acute kidney injury. Oncology 2012; 82: 354-359.
3. De Jongh FE, van Veen RN, Veltman SJ, et al: Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 2003; 88: 1199-1206.
4. Stewart DJ, Dulberg CS, Mikhael NZ, et al: Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 1997; 40: 293-308.
5. Rodrigues FB, Bruetto RG, Torres US, et al: Incidence and mortality of acute kidney injury after myocardial infarction: a comparison between KDIGO and RIFLE criteria. PLoS One 2013; 8:e69998.
6. Matsuo S, Imai E, Horio M, et al: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
7. Dalal S, Bruera E: Dehydration in cancer patients: to treat or not to treat. J Support Oncol 2004; 2: 467-479, 483.
8. La Manna G, Pancaldi LG, Capecchi A, et al: Risk for contrast nephropathy in patients undergoing coronarography. Artif Organs 2010; 34: 193-199.
9. Prescott GJ, Metcalfe W, Baharani J, et al: A prospective national study of acute renal failure treated with RRT: incidence, aetiology and outcomes. Nephrol Dial Transplant 2007; 22: 2513-2519.
10. McCullough PA, Haapio M, Mankad S, et al: Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant 2010; 25: 1777-1784.
11. Thakar CV, Christianson A, Himmelfarb J, et al: Acute kidney injury episodes and chronic kidney disease risk in DM. Clin J Am Soc Nephrol 2011; 6: 2567-2572.
12. Parolari A, Pesce LL, Pacini D, et al: Risk factors for perioperative acute kidney injury after adult cardiac surgery: role of perioperative management. Ann Thorac Surg 2012; 93: 584-591.
13. Bodnar L, Wcislo G, Gasowska-Bodnar A, et al: Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 2008; 44: 2608-2614.
14. Muraki K, Koyama R, Honma Y, et al: Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. J Thorac Dis 2012; 4: 562-568.
15. Filipski KK, Mathijssen RH, Mikkelsen TS, et al: Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 2009; 86: 396-402.